Please provide your email address to receive an email when new articles are posted on . Machine learning algorithms developed to predict improvement in patients with mild nonproliferative diabetic ...

New York, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Non-Proliferative Diabetic Retinopathy (NPDR) Disease - Global ...

BEDFORD, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to redefining the retina experience, outlined ...

Breye is advancing danegaptide to Phase II trials after the drug showed signs of improving disease activity in a Phase Ib ...

Breye Therapeutics ApS (Breye), a clinical-stage ophthalmology-focused biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, today announces clinical data ...

Findings of the PANORAMA randomized clinical trial show that when patients with severe nonproliferative diabetic retinopathy were treated with intravitreal aflibercept, severity improved over 100 ...

EyePoint Pharmaceuticals, Inc. stock surged following positive Phase 2 trial outcomes in wet AMD, showing non-inferiority to Eylea. Despite success in wet AMD, 1901 showed disappointing results in an ...

CHICAGO -- Diabetic patients without retinopathy achieved 20/20 vision after cataract surgery as often as nondiabetic patients did, a retrospective analysis of a large community-based cohort showed.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In this Healio Video Perspective from the ASRS meeting, ...

Assessing the potential of ocriplasmin to reduce risk of disease progression from NPDR to sight-threatening Proliferative Diabetic Retinopathy (PDR) ThromboGenics NV (Euronext Brussels: THR), an ...

Breye Therapeutics has reported promising early clinical findings for its lead oral therapy danegaptide, following a presentation at the Angiogenesis, Exudation and Degeneration 2026 symposium.

311 subjects enrolled across various stages of loading and randomization in SOL-R, Ocular’s second registrational trial of AXPAXLI™ in wet AMD, as of January 10, 2024 First wet AMD registrational ...